{"id":4296,"date":"2017-08-12T11:01:57","date_gmt":"2017-08-12T11:01:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/feasibility-of-deep-local-hyperthermia-treatment-in-conjunction-with-standard-cancer-treatments-and-patterns-of-response-esho\/"},"modified":"2025-09-04T16:20:18","modified_gmt":"2025-09-04T16:20:18","slug":"kliniskais-petijums-dzila-hipertermija","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/lv\/kliniskais-petijums-dzila-hipertermija\/","title":{"rendered":"Dzi\u013ca re\u0123ion\u0101l\u0101 hipertermija kombin\u0101cij\u0101 ar visu smadze\u0146u staru terapiju (WBRT) pacientiem ar sliktu prognozi un metast\u0101z\u0113m smadzen\u0113s"},"content":{"rendered":"

\u00a0Dzi\u013ca re\u0123ion\u0101l\u0101 hipertermija kombin\u0101cij\u0101 ar visu smadze\u0146u staru terapiju (WBRT) pacientiem ar sliktu prognozi un metast\u0101z\u0113m smadzen\u0113s<\/span><\/span><\/a><\/h1>\n

Kl\u012bniskais p\u0113t\u012bjums<\/h2>\n
\"kl\u012bniskais
Dzi\u013ca lok\u0101la hipertermija kombin\u0101cij\u0101 ar visu smadze\u0146u staru terapiju (WBRT) sliktas prognozes pacientiem ar metast\u0101z\u0113m smadzen\u0113s<\/span><\/span><\/figcaption><\/figure>\n

Kl\u012bnisk\u0101 p\u0113t\u012bjuma <\/span><\/span>kopsavilkums<\/span><\/span><\/strong><\/h2>\n

M\u0113r\u0137is:<\/span><\/span><\/strong> \u0160\u012b kl\u012bnisk\u0101 p\u0113t\u012bjuma m\u0113r\u0137is ir pirmo reizi nov\u0113rt\u0113t re\u0123ion\u0101l\u0101s dzi\u013c\u0101s hipertermijas lomu kombin\u0101cij\u0101 ar staru terapiju un sist\u0113misku terapiju pacientiem ar v\u0101jas prognozes smadze\u0146u metast\u0101z\u0113m (GPI\u22642,5).<\/span><\/span><\/p>\n

Metodes:<\/span><\/span><\/strong> \u0160aj\u0101 prospekt\u012bvaj\u0101 p\u0113t\u012bjum\u0101 tika iek\u013cauti pacienti ar apstiprin\u0101t\u0101m metast\u0101z\u0113m smadzen\u0113s, kuru GPI v\u0113rt\u0113jums bija \u22642,5. Pirmsapstr\u0101des stratifik\u0101cija tika defin\u0113ta k\u0101 pacienti ar GPI v\u0113rt\u0113jumu 0\u20131 (A grupa) un pacienti ar GPI v\u0113rt\u0113jumu 1,5\u20132,5 (B grupa). Hipertermija (HT) tika pielietota divas reizes ned\u0113\u013c\u0101, se\u0161desmit min\u016btes vien\u0101 seans\u0101, staru terapijas (RT) laik\u0101, izmantojot re\u0123ion\u0101lo kapacitat\u012bvo ier\u012bci ( <\/span><\/span>Andromedic <\/span><\/span><\/a> HyDeep 600WM hipertermijas ier\u012bci<\/span><\/span><\/a> ) ar 13,56 MHz radiofrekvenci.<\/span><\/span><\/p>\n

Rezult\u0101ti:<\/span><\/span><\/strong> Laik\u0101 no 2015.\u00a0gada j\u016bnija l\u012bdz 2017.\u00a0gada j\u016bnijam protokol\u0101 tika iek\u013cauti 15 pacienti un kopum\u0101 49 metast\u0101zes smadzen\u0113s. Visi pacienti sa\u0146\u0113ma visus HT sesijas, k\u0101 pl\u0101nots. Ar\u012b staru terapija un sist\u0113misk\u0101 terapija tika pabeigta, k\u0101 noteikts. <\/span><\/span>\u0100rst\u0113\u0161anas tolerance bija lieliska, un netika re\u0123istr\u0113ta toksicit\u0101te. Pacientiem ar HT efekt\u012bv\u0101s \u0101rst\u0113\u0161anas laiku, kas ilg\u0101ks par vid\u0113jo (W90 laiks > 88\u00a0%), bija lab\u0101ka aktu\u0101r\u0101 PFS p\u0113c 6 un 12 m\u0113ne\u0161iem (attiec\u012bgi 100\u00a0% un 66,7\u00a0%), sal\u012bdzinot ar tiem, kuriem bija maz\u0101ks HT efekt\u012bv\u0101s \u0101rst\u0113\u0161anas laiks (attiec\u012bgi 50\u00a0% un 0\u00a0%)<\/span><\/span><\/strong> (p\u00a0<\u00a00,031). Vid\u0113j\u0101 OS bija 6 m\u0113ne\u0161i (diapazons no 1 l\u012bdz 36 m\u0113ne\u0161iem). Stratifik\u0101cija p\u0113c GPI r\u0101d\u012bt\u0101ja uzr\u0101d\u012bja vid\u0113jo OS 3 m\u0113ne\u0161us (TI 95\u00a0% 2,49\u20133,51) A grup\u0101 un 8,0 m\u0113ne\u0161us (TI 95\u00a0% 5,1510,41) B grup\u0101 (p\u00a0=\u00a00,035).<\/span><\/span><\/p>\n

Secin\u0101jumi: <\/span><\/span><\/strong> Re\u0123ion\u0101l\u0101 hipertermija ir iesp\u0113jama un dro\u0161a metode, ko lietot kombin\u0101cij\u0101 ar staru terapiju pacientiem ar smadze\u0146u metast\u0101z\u0113m, uzlabojot dz\u012bvildzi bez slim\u012bbas progres\u0113\u0161anas (PFS) un izdz\u012bvo\u0161anu pacientiem ar sliktas prognozes smadze\u0146u metast\u0101z\u0113m.<\/span><\/span><\/strong><\/p>\n

 <\/p>\n

M\u016bsu p\u0113t\u012bjum\u0101 tika iek\u013cautas 49 smadze\u0146u metast\u0101zes no 15 pacientiem, kas pieder pie visnelabv\u0113l\u012bg\u0101kaj\u0101m GPA grup\u0101m: 6 pacientiem bija punktu indekss 0\u20131 (A grupa) un 9 pacientiem bija punktu indekss 1,5\u20132,5 (B grupa). Visi pacienti tika \u0101rst\u0113ti ar staru terapijas un re\u0123ion\u0101l\u0101s hipotermijas kombin\u0101ciju. M\u016bsu p\u0113t\u012bjuma pirmais secin\u0101jums ir t\u0101ds, ka kombin\u0113ta staru terapija un re\u0123ion\u0101l\u0101 hipotermija ir labi panesama \u0101rst\u0113\u0161anas metode pacientiem ar smadze\u0146u metast\u0101z\u0113m. Visas \u0101rst\u0113\u0161anas metodes tika veiktas, k\u0101 noteikts <\/span><\/span>.<\/span><\/span><\/strong><\/p>\n

HT izrais\u012bta toksicit\u0101te netika re\u0123istr\u0113ta. Turpret\u012b Byun et al. [13] sav\u0101 p\u0113t\u012bjum\u0101 par intraoperat\u012bvu HT aprakst\u012bja krampjus un br\u016b\u010du infekciju k\u0101 kombin\u0113t\u0101s \u0101rst\u0113\u0161anas komplik\u0101cijas iev\u0113rojam\u0101 skait\u0101 gad\u012bjumu. <\/span><\/span><\/strong> Dzi\u013ca hipertermija, \u0161\u0137iet, ir viegl\u0101k un dro\u0161\u0101k ievad\u0101ma nek\u0101 sare\u017e\u0123\u012bta intraoperat\u012bva \u0101rst\u0113\u0161ana<\/span><\/span><\/strong> .<\/span><\/span><\/p>\n

HT \u0101rst\u0113\u0161anas kvalit\u0101te (W90 laiks >88%) bija sp\u0113c\u012bg\u0101kais izdz\u012bvo\u0161anas prognoz\u0113jo\u0161ais faktors. T\u0101tad pacientiem, kuri sa\u0146\u0113ma >88% \u0101rst\u0113\u0161anas laika ar 90% no noz\u012bm\u0113t\u0101s jaudas (150 W), bija izcili dz\u012bvildzes bez slim\u012bbas progres\u0113\u0161anas r\u0101d\u012bt\u0101ji, kas apliecina HT lomu audz\u0113ju sensibiliz\u0101cij\u0101 pret radio\u0137\u012bmijterapiju [4\u20137].<\/span><\/span><\/p>\n

Saska\u0146\u0101 ar kop\u0113jo dz\u012bvildzi, m\u016bsu s\u0113rij\u0101 vid\u0113j\u0101 kop\u0113j\u0101 dz\u012bvildze bija 6 m\u0113ne\u0161i, uzlabojot standarta \u0101rst\u0113\u0161anas sliktos rezult\u0101tus \u0161ajos gad\u012bjumos [3]. Hipertermijas saist\u012bba ar staru terapiju (RT +\/-) sist\u0113misku \u0101rst\u0113\u0161anu m\u016bsu smadze\u0146u kaulu smadze\u0146u pacientiem sasniedza 53,1% izdz\u012bvo\u0161anas varb\u016bt\u012bbu p\u0113c 6 m\u0113ne\u0161iem un 30,6% p\u0113c 12 m\u0113ne\u0161iem<\/span><\/span><\/strong> .<\/span><\/span><\/p>\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/32748093\/<\/span><\/span><\/p>\n

https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02404-9<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0Dzi\u013ca re\u0123ion\u0101l\u0101 hipertermija kombin\u0101cij\u0101 ar visu smadze\u0146u staru terapiju (WBRT) pacientiem ar sliktu prognozi un metast\u0101z\u0113m smadzen\u0113s Kl\u012bniskais p\u0113t\u012bjums Kl\u012bnisk\u0101 p\u0113t\u012bjuma kopsavilkums M\u0113r\u0137is: \u0160\u012b kl\u012bnisk\u0101 p\u0113t\u012bjuma m\u0113r\u0137is ir pirmo reizi nov\u0113rt\u0113t re\u0123ion\u0101l\u0101s dzi\u013c\u0101s hipertermijas lomu kombin\u0101cij\u0101 ar staru terapiju un sist\u0113misku terapiju pacientiem ar v\u0101jas prognozes smadze\u0146u metast\u0101z\u0113m (GPI\u22642,5). Metodes: \u0160aj\u0101 prospekt\u012bvaj\u0101 p\u0113t\u012bjum\u0101 tika iek\u013cauti…<\/p>\n","protected":false},"author":1,"featured_media":7046,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[172],"tags":[],"class_list":["post-4296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-lv"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts\/4296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/comments?post=4296"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts\/4296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/media\/7046"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/media?parent=4296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/categories?post=4296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/tags?post=4296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}